Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

Ju Dong Yang, MD, MSc
Published: Wednesday, Sep 14, 2016



Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Researchers confirmed a strong association between NASH etiologies and a lack of cirrhosis at the time of HCC diagnosis, which was a major finding, according to Yang.

The data demonstrated a potential need for liver cancer surveillance in this subset of patients who have smoked in the past, or are currently smoking, as they may be at a higher risk of developing liver cancer, even in the absence of cirrhotic liver disease.


Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Researchers confirmed a strong association between NASH etiologies and a lack of cirrhosis at the time of HCC diagnosis, which was a major finding, according to Yang.

The data demonstrated a potential need for liver cancer surveillance in this subset of patients who have smoked in the past, or are currently smoking, as they may be at a higher risk of developing liver cancer, even in the absence of cirrhotic liver disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x